Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.50
Bid: 1,604.00
Ask: 1,604.50
Change: 4.50 (0.28%)
Spread: 0.50 (0.031%)
Open: 1,600.50
High: 1,612.50
Low: 1,591.00
Prev. Close: 1,595.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK retail sales fall amid wet April; Co-Op Bank deal

Fri, 24th May 2024 07:52

(Alliance News) - Stocks are called to open lower on Friday, following New York lower, as hopes of interest rate cuts have come into question.

In early economic news, UK retail sales fell in April, as miserable weather kept shoppers at home, according to a first estimate.

There was some good news for GSK, with the firm welcoming the jury verdict in the Valadez case in Illinois state court. The case was in GSK's favour.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 0.9% at 8,263.60

----------

Hang Seng: down 1.6% at 18,568.15

Nikkei 225: closed down 1.2% at 38,646.11

S&P/ASX 200: closed down 1.1% at 7,727.60

----------

DJIA: closed down 605.78 points, or 1.5%, at 39,065.26

S&P 500: closed down 39.17 points, or 0.7%, at 5,267.84

Nasdaq Composite: closed down 65.51 points, or 0.4%, at 16,736.03

----------

EUR: down at USD1.0810 (USD1.0830)

GBP: down at USD1.2690 (USD1.2710)

USD: down at JPY157.08 (JPY157.13)

Gold: down at USD2,337.70 per ounce (USD2,340.90)

(Brent): down at USD81.33 a barrel (USD81.58)

(changes since previous London equities close)

----------

ECONOMICS

----------

Friday's key economic events still to come:

08:30 EDT Canada retail sales

08:45 CEST France business confidence

09:00 CEST Spain PPI

08:30 EDT US durable goods orders

----------

UK retail sales fell in April, as miserable weather kept shoppers at home, according to a first estimate on Friday. Retail sales fell by 2.7% in April from a year prior, the Office for National Statistics said. Sales had increased by 0.4% on-year in March, being revised up from being flat previously. According to FXStreet, retail sales were expected to fall by just 0.2% annually in April. Sales fell by 2.3% in April from March, following a 0.2% fall in March from February. March's reading was worse than consensus of just a 0.4% slip. "Sales volumes fell across most sectors, with clothing retailers, sports equipment, games and toys stores, and furniture stores doing badly as poor weather reduced footfall," the ONS said.

----------

The Tory and Labour parties clashed on energy policy for the UK as the general election campaign focused on the prospect of cheaper household bills. Labour leader Keir Starmer is using a visit to Scotland to promote his plan for a publicly-owned green electricity generator, which he said would cut bills and boost energy security. Energy Secretary Claire Coutinho set out plans for consumer-friendly changes and accused Labour of not being "honest about the costs" that their plans for net zero power would involve. The row came as regulator Ofgem early Friday set out the latest level for the energy price cap on average bills. The watchdog said the average household energy bill will drop by around 7% from July 1, when the latest change to the price cap takes effect. This means the average UK household will pay GBP122 less per year.

----------

BROKER RATING CHANGES

----------

HSBC cuts Aviva to 'hold' - price target 525 pence

----------

Berenberg starts Andrada Mining with 'buy' - price target 10 pence

----------

HSBC cuts Midwich Group to 'hold' - price target 425 pence

----------

COMPANIES - FTSE 100

----------

GSK welcomed the jury verdict in the Valadez case in Illinois state court finding in GSK's favour in the first Zantac case to go to trial. "This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine," GSK said. It added that it "will continue to vigorously defend itself against all other claims." Zantac was a heartburn drug that was pulled off the market in 2020 at the request of the US Food & Drug Administration, after low levels of a "probable carcinogen" were found in samples. The carcinogen, known as NDMA, is not harmful in very small amounts. However, tests showed that there were excessive quantities of NDMA in ranitidine, otherwise known as Zantac. Multiple litigations have followed. Also on Friday, GSK said that findings across its oncology portfolio will be presented in 25 abstracts at the 2024 American Society of Clinical Oncology annual meeting.

----------

Intertek said that between January and April it reported revenue of GBP1.08 billion, representing growth of 7.5% at constant currency and 2.0% at actual rates. It said margin progression was driven by pricing, operating leverage, cost controls and productivity improvements. Looking ahead, Intertek reconfirmed 2024 outlook. CEO Andre Lacroix said: "We expect the group will deliver a robust performance with mid-single digit LFL revenue growth at constant currency, margin progression and a strong cash flow performance. We are well positioned to get back to our peak margin of 17.5% and beyond in the medium-term, capitalising on the revenue growth acceleration we are seeing for our ATIC solutions, our disciplined performance management and our investments in high growth and high margin segments."

----------

COMPANIES - FTSE 250

----------

John Wood said it has received a third unsolicited, preliminary and conditional proposal from Dar Al-Handasah Consultants Shair & Partners Holdings Ltd, known as Sidara, for a cash offer of 220 pence per Wood share. This represents an increase of approximately 3.8% to the previous proposal of 212 pence per Wood share submitted on May 14. The company said the new offer "continued to significantly undervalue the group and its prospects." It has therefore rejected the proposal.

----------

abrdn said that Stephen Bird as stepped down as CEO, after four years in the role. Jason Windsor, currently chief financial officer, has been appointed as interim CEO. It has also launched a formal search process for a permanent CEO, which includes the consideration of external candidates. Chair Douglas Flint said: "Jason brought significant and relevant leadership experience to abrdn and since his arrival last year has made a strong start. The board looks forward with confidence to working with him in his new role as our interim group CEO."

----------

OTHER COMPANIES

----------

Coventry Building Society said it has agreed to buy Co-operative Bank in a GBP780 million deal. Coventry Building Society said owners of 88% of Co-operative Bank A shares agreed to the takeover, whilst owners of 100% of B shares agreed. It noted that up to GBP125 million of Co-operative Bank cash payment is deferred over three years. It added that Coventry Building Society will remain as a building society following the Co-operative Bank takeover. The acquisition is expected to complete in the first quarter of 2025. Coventry Building Society CEO Steve Hughes said: "By bringing together Coventry Building Society and The Co-operative Bank we will be able to deliver more value to more people in the coming years. I am excited about the opportunities that lie ahead, most importantly, our ability to sustain the great value and outstanding service that matters most to our members."

----------

Tribal Group said it has reached a settlement agreement with Nanyang Technological University. Without admission of liability, the Bristol-based educational software and services provider has agreed to pay to NTU GBP3.1 million in full and final settlement, over the next 18 months.

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
16 Apr 2024 09:17

GSK meningococcal vaccine accepted by US FDA for review

(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).

Read more
16 Apr 2024 08:59

GSK's latest meningitis vaccine accepted for review by US regulator

(Alliance News) - GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths of two other vaccines in its portfolio into one bacteria-fighting inoculation.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
9 Apr 2024 11:45

Pfizer RSV shot meets goals in trial of high-risk adults under age 60

April 9 (Reuters) - Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60 similar to that in older adults, for whom the shot is already approved.

Read more
8 Apr 2024 09:13

LONDON BROKER RATINGS: Wizz Air raised; HSBC cuts Rentokil to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
4 Apr 2024 13:08

UK dividends calendar - next 7 days

Friday 5 April 
BBGI Global Infrastructure SAdividend payment date
Molten Ventures PLCdividend payment date
Pennon Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
Regional REIT Ltddividend payment date
Rights & Issues Investment Trust PLCdividend payment date
Sylvania Platinum Ltddividend payment date
Titon Holdings PLCdividend payment date
Triple Point Energy Transition PLCdividend payment date
Monday 8 April 
Alumasc Group PLCdividend payment date
LondonMetric Property PLCdividend payment date
Redrow PLCdividend payment date
Tuesday 9 April 
CT Global Managed Portfolio Trust PLCdividend payment date
Downing Strategic Micro-Cap Investment Trust PLCdividend payment date
Dunelm Group PLCspecial dividend payment date
Hays PLCdividend payment date
Renishaw PLCdividend payment date
Safestore Holdings PLCdividend payment date
Wednesday 10 April 
Assura PLCdividend payment date
Primorus Investments PLCspecial dividend payment date
Wilmington PLCdividend payment date
Thursday 11 April 
Amedeo Air Four Plus Ltdex-dividend payment date
Athelney Trust PLCdividend payment date
Aviva PLCex-dividend payment date
Balanced Commercial Property Trust Ltdex-dividend payment date
Barratt Developments PLCex-dividend payment date
Begbies Traynor Group PLCex-dividend payment date
Bioventix PLCex-dividend payment date
Blackfinch Spring VCT PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
Caledonia Mining Corpex-dividend payment date
Capital & Regional PLCex-dividend payment date
Chesnara PLCex-dividend payment date
Colefax Group PLCdividend payment date
CT Private Equity Trust PLCex-dividend payment date
Downing Strategic Micro-Cap Investements Trust PLCex-dividend payment date
Driver Group PLCdividend payment date
F&C Investment Trust PLCex-dividend payment date
Foxtons Group PLCex-dividend payment date
Grafton Group PLCex-dividend payment date
GSK PLCdividend payment date
Harbour Energy PLCex-dividend payment date
Hargreaves Services PLCdividend payment date
Howden Joinery Group PLCex-dividend payment date
Hunting PLCex-dividend payment date
i3 Energy PLCex-dividend payment date
International Personal Finance PLCex-dividend payment date
International Public Partnerships Ltdex-dividend payment date
ITV PLCex-dividend payment date
Johnson Service Group PLCex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
JPMorgan Japan Small Cap Growth & Income PLCex-dividend payment date
Just Group PLCex-dividend payment date
Kenmare Resources PLCex-dividend payment date
Kerry Group PLCex-dividend payment date
Kings Arms Yard VCT PLCex-dividend payment date
Law Debenture Corp PLCdividend payment date
Lloyds Banking Group PLCex-dividend payment date
Lowland Investment Cos PLCex-dividend payment date
Luceco PLCex-dividend payment date
Man Group PLCex-dividend payment date
Manchester & London Investement Trust PLCex-dividend payment date
Marble Point Loan Financing Ltdex-dividend payment date
Mercantile Investment Trust PLCex-dividend payment date
Mobius Investment Trust PLCex-dividend payment date
MTI Wireless Edge Ltddividend payment date
North American Income Trust PLCex-dividend payment date
Northamber PLCex-dividend payment date
Octopus Apollo VCT PLCex-dividend payment date
Phoenix Group Holdings PLCex-dividend payment date
Reckitt Benckiser Group PLCex-dividend payment date
Ricardo PLCdividend payment date
Savills PLCex-dividend payment date
Schroder Asian Total Return Investment Cos PLCex-dividend payment date
Schroder European Real Estate Investment Trust PLCex-dividend payment date
Scottish American Investment Cos PLCdividend payment date
Smurfit Kappa Group PLCex-dividend payment date
Softcat PLCex-dividend payment date
Somero Enterprises Incex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Synectics PLCex-dividend payment date
TP ICAP Group PLCex-dividend payment date
Trifast PLCdividend payment date
TT Electronics PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.